Advisory Research’s Precigen PGEN Stock Holding History

Advisory Research’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-45,382	Closed	-$97K	–	396
2022 Q3	$97K	Buy	+45,382	New	+$95.7K	0.01%	325

Other funds holding PGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Advisory Research's PGEN Position: Q4 2022 in Review

Advisory Research sold out of Precigen (PGEN) in Q4 2022, closing a stake of 45,382 shares — an estimated $97K sold.

Advisory Research first reported a position in PGEN in Q3 2022 and held it in 1 quarter. The position peaked at $97K in Q3 2022. 161 funds tracked by Wall St. Rank hold PGEN as of Q4 2022.

Advisory Research reported no remaining Precigen position as of Q4 2022 after selling out during the quarter.
Advisory Research sold 45,382 Precigen shares in Q4 2022, an estimated $97K.
Advisory Research first reported a position in Precigen in Q3 2022 and held it in 1 quarter.
Advisory Research's Precigen position peaked at $97K in Q3 2022.
161 funds tracked by Wall St. Rank held Precigen as of Q4 2022.

Based on Advisory Research's 13F filing for Q4 2022, filed 13 Feb 2023.